PULMONARY SPOROTRICHOSIS - TREATMENT WITH MICONAZOLE

Abstract

I.v. miconazole, an investigational, broad-spectrum, antifungal imidazole drug, was clinically effective when used for the 1st time in a patient with life-threatening sporotichosis. Miconazole was used after drug resistance and treatment failure occurred in a patient with extensive, cavitary, pulmonary infection with Sporotrichum schenckii. He was 1st treated with amphotericin B, and then with amphotericin B and flucytosine in combination. Side effects of miconazole included itching, diarrhea and phlebitis. Clinical improvement occurred despite plasma concentrations below those needed for complete inhibition of the patient''s organisms in vitro.